OFORTA
LOE ApproachingNDAORALTABLET
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OFORTA is an oral small-molecule tablet approved by the FDA in December 2008 under a New Drug Application (NDA) by Sanofi. The mechanism of action and specific indications are not publicly available in standard databases, limiting assessment of its therapeutic category and patient population.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling potential downsizing or transition planning on the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OFORTA currently has zero linked job openings, reflecting its mature LOE-approaching lifecycle stage. Career opportunities are limited and likely declining; positions on this product typically focus on managing decline, protecting remaining market share, and preparing for generic transition.
Brand ManagerField Sales Representative
Worked on OFORTA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.